Phase 1/2a clinical trials of MVA-based H5N1 vaccine

Joost H C M Kreijtz, Marco Goeijenbier, Fleur M Moesker, Lennert van den Dries, Simone Goeijenbier, Heidi L M De Gruyter, Michael H Lehmann, Gerrie de Mutsert, David A M C van de Vijver, Asisa Volz, Ron A M Fouchier, Eric C M van Gorp,  Guus F Rimmelzwaan, Gerd Sutter, Albert D M E Osterhaus (2014) Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trialThe Lancet Infectious Diseases in press (corrected proof) DOI: 10.1016/S1473-3099(14)70963-6

Promising results in the Journal of Infectious Diseases!

J.H.C.M. Kreijtz, L.C.M. Wiersma, H.L.M. Gruyter De, S.E. Vogelzang-van Trierum, G. van Amerongen, K.J. Stittelaar, R.A.M. Fouchier, A.D.M.E. Osterhaus, G. Sutter and G.F. Rimmelzwaan (2014) A single immunization with a modified Vaccinia Virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. The Journal of Infectious Diseases 10.1093/infdis/jiu528